Immunocore

The company develops transformative immunomodulating medicines using its proprietary ImmTAX technology, which utilizes modular T cell receptor (TCR) bispecific therapies. These therapies are designed to activate the immune system to destroy infected or tumor cells, or to reduce autoimmune responses by turning the immune system off. The product pipeline targets patients with solid tumors, infectious diseases, and autoimmune diseases, including specific treatments for metastatic uveal melanoma.